KIMS Announces Investor Presentation for FY26 Audited Results
KIMS Hospitals released its audited FY26 results presentation. FY26 revenue reached ₹3,930.8 crore, with EBITDA at ₹828.2 crore and PAT at ₹242.0 crore. The company highlighted its growth strategy, regional performance, and operational metrics, including bed capacity and occupancy rates.
The announcement provides detailed financial results for the fiscal year, which is crucial information for investors to assess the company's performance and future prospects.
The announcement is a routine disclosure of financial results and an investor presentation, providing factual information without any explicit positive or negative commentary.
Krishna Institute of Medical Sciences Limited (KIMS) has released an investor presentation detailing the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The presentation is available on the company's website under the investors section.
The company has provided detailed financial and operational highlights for FY24, FY25, and FY26. For FY26, total revenue stood at ₹3,930.8 crore (39,308 million), with EBITDA at ₹828.2 crore (8,282 million) and a PAT of ₹242.0 crore (2,420 million). The presentation also details operational metrics such as IP volume, OP volume, ARPOB, and ARPP for the respective periods. A breakdown of performance by region (Telangana, Andhra Pradesh, Maharashtra, Kerala, Karnataka) is also included.
The company's journey and strategic levers for future growth are highlighted, emphasizing consistent performance, expansion through greenfield projects, acquisitions, and operations & maintenance (O&M) opportunities, alongside strategic doctor partnerships. The presentation also showcases the company's extensive network of hospitals, corporate structure, revenue mix, and speciality focus.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.